DDW: Gastroenterologists missing chances to shift to generic meds

DDW: gastroenterologists missing chances to shift to generic meds

(HealthDay)—Although most gastroenterologists feel that store-brand and branded treatments are equivalent, most continue to recommend branded products for gastroesophageal reflux disease (GERD) and chronic constipation, according to two studies presented at the annual Digestive Disease Week, held from May 3 to 6 in Chicago.

Amanda Guentner, M.D., from the University of Michigan Health System in Ann Arbor, surveyed 830 gastroenterologists about their perceptions and practices regarding store-brand versus branded over-the-counter (OTC) medications for GERD. The researchers found that 72 percent of gastroenterologists felt that there was equal bioequivalence for store-brand and branded (PPIs), and 76 percent felt that their effectiveness was equivalent. However, more than 30 percent of the time 54 percent of gastroenterologists recommended a branded OTC PPI to patients with typical GERD symptoms. The associated with store-brand versus branded treatments were underestimated by gastroenterologists.

In a second study, Guentner and colleagues examined utilization of store-brand and branded OTC and prescription medications for in a survey of 830 gastroenterologists. The researchers found that, although 90 percent of gastroenterologists felt that store-brand and branded polyethylene glycol laxatives were equally effective, only 40 percent of gastroenterologists always or often encouraged their patients to purchase store-brand laxatives. The cost savings associated with store-brand laxatives were underestimated by .

"At a time when doctors are highly constrained in their use of prescription medicines for so-called lifestyle conditions like GERD and constipation, treatment of these conditions is going to shift more and more to the OTC space," a coauthor on both studies said in a statement.

More information: Press Release
More Information

add to favorites email to friend print save as pdf

Related Stories

AGA publishes tool to help GIs manage HCV patients

Nov 05, 2013

The American Gastroenterological Association (AGA) Clinical Decision Tool for the Screening and Evaluation of Hepatitis C (HCV) will help gastroenterologists in the early management of HCV-positive patients, according to ...

Brand name advertising clicks with online shoppers

Oct 03, 2011

(PhysOrg.com) -- Brand names in online search engine advertising campaigns can attract more attention and encourage more sales than campaigns that use generic terms, according to Penn State researchers.

Prescription problems for vets on reflux drug

Feb 20, 2013

U.S. veterans diagnosed with gastroesophageal reflux disease (GERD) are frequently prescribed doses of proton pump inhibitors (PPIs), such as omeprazole (commonly known by brand names such as Prilosec), that are much higher ...

Recommended for you

Determine patient preferences by means of conjoint analysis

9 hours ago

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

User comments